Abstract
Background: Currently, existing regimens of genotoxic drugs have been suggested to be complemented with molecular inhibitors as combinatorial and cocktail approaches in malignancy.
Methods: In the last decade, attempts have been reported to test several new class of anticancer drug such as miRNA mimetics, RNA enzymes, small molecular inhibitors, DNA repair protein inhibitors and peptide mimetics.
Results: With the advent of rapidly growing genomic, epigenomic and proteomic data, design and application of peptide mimetics appear to thrive and sustain for an impactful cancer therapy. However, certain bottlenecks are envitable such as delivery of peptide mimetics drug in clinical settings, reducing the side effects, immune responses and pharmacokinetic properties.
Conclusion: This review discusses emerging issues and potential avenues related to the scope and limitations of peptide mimetics in cancer treatment.
Keywords: Cellular growth, cancer, proteomics, protein, regulation, signaling pathway, targeted therapy.
Current Cancer Therapy Reviews
Title:Therapeutic Peptide Mimetics Looking for a Turn to Block Aberrant Players of Malignancy
Volume: 13 Issue: 2
Author(s): Pritish Nilendu, Sayantani Roychoudhary, Karishma Deshpande and Nilesh K. Sharma*
Affiliation:
- Cancer and Translational Research Lab, Dr. D.Y. Patil Biotechnology & Bioinformatics Institute, Dr. D.Y. Patil Vidyapeeth, Pune, Maharashtra,India
Keywords: Cellular growth, cancer, proteomics, protein, regulation, signaling pathway, targeted therapy.
Abstract: Background: Currently, existing regimens of genotoxic drugs have been suggested to be complemented with molecular inhibitors as combinatorial and cocktail approaches in malignancy.
Methods: In the last decade, attempts have been reported to test several new class of anticancer drug such as miRNA mimetics, RNA enzymes, small molecular inhibitors, DNA repair protein inhibitors and peptide mimetics.
Results: With the advent of rapidly growing genomic, epigenomic and proteomic data, design and application of peptide mimetics appear to thrive and sustain for an impactful cancer therapy. However, certain bottlenecks are envitable such as delivery of peptide mimetics drug in clinical settings, reducing the side effects, immune responses and pharmacokinetic properties.
Conclusion: This review discusses emerging issues and potential avenues related to the scope and limitations of peptide mimetics in cancer treatment.
Export Options
About this article
Cite this article as:
Nilendu Pritish, Roychoudhary Sayantani , Deshpande Karishma and Sharma K. Nilesh *, Therapeutic Peptide Mimetics Looking for a Turn to Block Aberrant Players of Malignancy, Current Cancer Therapy Reviews 2017; 13 (2) . https://dx.doi.org/10.2174/1573394713666170615115259
DOI https://dx.doi.org/10.2174/1573394713666170615115259 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Radiotracers in Oncology
Current Radiopharmaceuticals Radiotherapy in Transitional Cell Carcinoma of Urinary Bladder Cancer –Where Does it Fit Into Treatment Protocol
Current Cancer Therapy Reviews Progresses in TCM Metal-Based Antitumour Agents
Anti-Cancer Agents in Medicinal Chemistry Drug Targets to Pro-Angiogenetic Factors with Special Reference to Primary Peritoneal Mesothelioma
Endocrine, Metabolic & Immune Disorders - Drug Targets Ghrelin: A Gastric Peptide that Regulates Hypothalamic Control of Feeding
Current Medicinal Chemistry - Central Nervous System Agents Insights on Antimicrobial Resistance, Biofilms and the Use of Phytochemicals as New Antimicrobial Agents
Current Medicinal Chemistry Competition Between Tumor and Mononuclear Phagocyte System Causing the Low Tumor Distribution of Nanoparticles and Strategies to Improve Tumor Accumulation
Current Drug Delivery FOXM1 and its Oncogenic Signaling in Gastric Cancer
Recent Patents on Anti-Cancer Drug Discovery Bone Seeking Radiopharmaceuticals for Palliation of Pain in Cancer Patients with Osseous Metastases
Anti-Cancer Agents in Medicinal Chemistry Will Arsenic Trioxide Benefit Treatment of Solid Tumor by Nano- Encapsulation?
Mini-Reviews in Medicinal Chemistry The Therapeutic Potential of Small Activating RNAs for Colorectal Carcinoma
Current Gene Therapy Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review
Current Pharmaceutical Biotechnology 1,3,5-Triazine Analogs: A Potent Anticancer Scaffold
Current Signal Transduction Therapy Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets The Potential of 11C-acetate PET for Monitoring the Fatty Acid Synthesis Pathway in Tumors
Current Pharmaceutical Biotechnology Metallothioneins and Platinum(II) Anti-Tumor Compounds
Current Medicinal Chemistry Organic Synthesis and Antisense Effects of Oligonucleotide-Peptide Conjugates
Current Organic Chemistry Role of Polysaccharides Mimetic Components in Targeted Cancer Treatment
Current Drug Targets Muscarinic Acetylcholine Receptors: New Potential Therapeutic Targets in Antinociception and in Cancer Therapy
Recent Patents on CNS Drug Discovery (Discontinued) Biochemical Properties of Indoleamine 2,3-dioxygenase: From Structure to Optimized Design of Inhibitors
Current Medicinal Chemistry